One such brand, Bath and Body Works, known for its body essentials and fragrances, attracted huge crowds over the weekend.

Pharmaceutical exports are expected to continue on a healthy trajectory over the next few years with products worth over $250 ...

Outliers 2025 by Outlook Business reveals how Wockhardt’s $700M push into antibiotic innovation is paying off, with Zaynich ...

Mercedes Ruehl So Swiss prosecutors have filed charges against Credit Suisse — by extension UBS, which took Credit Suisse ...

Britain's attitude towards its medicines industry has long been strangely cool. The NHS has preferred cut price generic drugs ...

The UK and the US have agreed a deal to keep tariffs on UK pharmaceutical imports into the America at zero. Under the agreement the UK will pay more for medicines through the NHS in return for a ...

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.

Discover why Harrow Inc. (HROW) is a strong buy in 2024—explosive growth from Vevye, rising margins, and a $175 price target.

A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.

Wockhardt shares were trading 18.31% higher at Rs 1459.4 per share on BSE with a market capitalisation of Rs 23,713.14 crore ...

The OBR chief’s resignation, a rebound in UK manufacturing, and a major UK-US pharma deal led London markets today. Tesla saw ...

According to The New England Journal of Medicine, investigators at Uppsala University Hospital implanted a product called ...